Vertex Second Phase II Study Supports Telaprevir 24-Week Regimen
Adverse events associated with the hep C treatment are “troublesome,” not “troubling,” Vertex CEO Boger says.
Adverse events associated with the hep C treatment are “troublesome,” not “troubling,” Vertex CEO Boger says.